Eli Lilly will withdraw its sepsis medication Xigris following results from a recent study that showed no benefit in taking the drug.

The PROWESS-SHOCK study, which enrolled 1,696 patients, showed the drug did not meet the primary endpoint of a statistically-significant reduction in 28-day all-cause mortality in patients suffering from septic shock.

Lilly undertook the trial in order to gain continued market authorisation for Europe following its 2002 approval but the drug, which was originally approved for use in the US in November 2001, will now be withdrawn.

Once touted as a potential blockbuster, Xigris achieved sales of $104m last year.

Lilly now expects to incur a charge of between $75-95m due to the withdrawl.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.